Akebia Therapeutics Crecimiento futuro

Future controles de criterios 4/6

Akebia Therapeutics se prevé un crecimiento anual de los beneficios y los ingresos de 61.3% y 15.2%, respectivamente, mientras que el BPA aumentará de grow a 60.6%.

Información clave

60.2%

Tasa de crecimiento de los beneficios

61.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.7%
Tasa de crecimiento de los ingresos	17.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	28 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Apr 02

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Mar 19

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Jan 05

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Jun 23

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Mar 02

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Oct 07

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Aug 10

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Jun 30

Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?

May 26

Akebia EPS misses by $0.08, beats on revenue

May 10

Akebia highlights late-stage vadadustat kidney disease study results

Apr 28

Akebia Therapeutics, Inc. (NASDAQ:AKBA): When Will It Breakeven?

Mar 31

Have Insiders Been Selling Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares This Year?

Mar 10

Have Insiders Sold Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Recently?

Mar 10

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:AKBA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	237	38	N/A	N/A	2
12/31/2025	171	-63	N/A	-67	3
12/31/2024	189	-63	N/A	-29	3
12/31/2023	195	-52	-23	-23	N/A
9/30/2023	194	-59	-76	-76	N/A
6/30/2023	201	-98	-35	-35	N/A
3/31/2023	271	-56	-69	-69	N/A
12/31/2022	292	-94	-73	-73	N/A
9/30/2022	294	-158	-81	-81	N/A
6/30/2022	294	-163	-171	-171	N/A
3/31/2022	221	-276	-204	-204	N/A
12/31/2021	212	-282	-253	-253	N/A
9/30/2021	211	-299	-221	-221	N/A
6/30/2021	222	-300	-192	-192	N/A
3/31/2021	259	-392	-92	-92	N/A
12/31/2020	295	-385	-111	-110	N/A
9/30/2020	308	-391	-172	-172	N/A
6/30/2020	340	-386	-136	-134	N/A
3/31/2020	351	-268	-214	-209	N/A
12/31/2019	335	-280	-264	-257	N/A
9/30/2019	325	-245	-246	-239	N/A
6/30/2019	286	-217	-267	-262	N/A
3/31/2019	234	-193	-218	-215	N/A
12/31/2018	208	-144	-99	-97	N/A
9/30/2018	238	-68	-41	-40	N/A
6/30/2018	227	-65	-84	-82	N/A
3/31/2018	206	-53	-68	-67	N/A
12/31/2017	181	-74	-58	-56	N/A
9/30/2017	92	-127	N/A	56	N/A
6/30/2017	51	-140	N/A	82	N/A
3/31/2017	22	-154	N/A	31	N/A
12/31/2016	2	-136	N/A	58	N/A
9/30/2016	N/A	-118	N/A	-61	N/A
6/30/2016	N/A	-101	N/A	-41	N/A
3/31/2016	N/A	-76	N/A	-27	N/A
12/31/2015	N/A	-61	N/A	-52	N/A
9/30/2015	N/A	-51	N/A	-39	N/A
6/30/2015	N/A	-41	N/A	-35	N/A
3/31/2015	N/A	-38	N/A	-30	N/A
12/31/2014	N/A	-124	N/A	-27	N/A
9/30/2014	N/A	-123	N/A	-23	N/A
6/30/2014	N/A	-120	N/A	-21	N/A
3/31/2014	N/A	-164	N/A	-16	N/A
12/31/2013	N/A	-69	N/A	-11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: AKBA se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios frente mercado: AKBA se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: AKBA se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: AKBASe prevé que los ingresos de la empresa (10.4% al año) crezcan más deprisa que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: AKBASe prevé que los ingresos de la empresa (10.4% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la Rentabilidad de los fondos propios de AKBA se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Akebia Therapeutics Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Price target increased by 12% to US$4.33

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Price target increased by 29% to US$3.88

Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023

Recent updates

Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)

Akebia Therapeutics, Inc. Receives FDA Approval of Vafseo (vadadustat) Tablets for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise

Full year 2023 earnings: EPS exceeds analyst expectations

Akebia Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Akebia Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

CEO, President & Director recently sold US$74k worth of stock

CEO, President & Director notifies of intention to sell stock

Price target increased by 12% to US$4.33

CEO, President & Director recently sold US$78k worth of stock

Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Price target increased by 29% to US$3.88

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akebia Therapeutics, Inc. Announces Five Poster Presentations at ASN Kidney Week 2023

Akebia Therapeutics, Inc. Revises Revenue Guidance for the Year 2023

Akebia Therapeutics, Inc. to Report Q2, 2023 Results on Aug 25, 2023

Akebia Therapeutics, Inc. announced delayed 10-Q filing

Akebia Therapeutics, Inc. Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia®? (ferric Citrate) for In-Center and Home Dialysis Patients

Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump

Akebia Therapeutics, Inc. Announces Swissmedic Approval of Vafseo Vadadustat

Akebia Therapeutics, Inc. Announces Executive Changes

Senior VP & COO recently sold US$117k worth of stock

Consensus estimates of losses per share improve by 15%

Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Akebia Therapeutics, Inc. Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis

Principal Accounting Officer recently sold US$68k worth of stock

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.33 loss

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023

Price target increased by 23% to US$2.00

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CEO, President & Director recently sold US$81k worth of stock

Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?

Akebia Therapeutics, Inc. Receives Interim Response to Appeal for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease from the FDA

Akebia Therapeutics, Inc. Announces Executive Changes

Insufficient new directors

Akebia Therapeutics, Inc. Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akebia Therapeutics, Inc. Affirms Revenue Guidance for the Year 2022

Akebia Therapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky

Consensus forecasts updated

Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher

Akebia Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with Covid-19 and Hypoxemia (VSTAT)

Akebia Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target decreased to US$1.63

Insufficient new directors

Akebia regains rights to kidney disease therapy after termination of deals with Otsuka

Akebia Therapeutics Receives Non-Compliance Notice from Nasdaq

Akebia Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Akebia Therapeutics, Inc

Akebia Therapeutics, Inc. Approves Reduction of the Workforce by Approximately 42%

Consensus forecasts updated

Akebia Therapeutics Receives Complete Response Letter from the FDA for Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients

Consensus EPS estimates fall by 16%

Full year 2021 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Akebia Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Insufficient new directors

Forecast to breakeven in 2024

Price target increased to US$7.40